Basecamp Research Appoints John Finn, Ph.D., as CSO,

Basecamp Research Expands its leadership Team and Footprint to Accelerate Development of Programmable Genetic Medicines

London and cambridge, Mass. – January 6, 2025 – Basecamp Research, a leading AI-driven life sciences company, today announced the appointment of John Finn, Ph.D., as its Chief Scientific Officer (CSO). This strategic hire coincides wiht the opening of a new lab and office in Boston’s renowned Kendall Square biotechnology hub,signifying Basecamp’s increased commitment to pioneering advancements in genetic medicine.

A Visionary Leader in Gene and Cell Therapy

Dr. Finn brings over 25 years of experiance in cell and gene therapy to Basecamp Research. Most recently,he served as Chief scientific Officer of Tome Biosciences,where he spearheaded innovative large gene insertion methods for therapeutic applications. Prior to this, Dr. Finn held senior leadership roles at codiak BioSciences and Intellia Therapeutics, consistently pushing the boundaries of gene and cell therapy delivery and editing technologies.

“John is a globally recognized leader in cell and gene therapy who has dedicated his career to tackling complex scientific and technological challenges,” said Glen Gowers, Ph.D., Basecamp Research co-founder and CEO. “With John’s expertise, our vast data advantage, and our pioneering new class of foundation models, Basecamp Research is well-positioned to transcend known biological limitations and achieve groundbreaking advances that will improve human health.”

Excited by the opportunity,Dr. Finn stated, “I was drawn to Basecamp Research by the amazing opportunity to develop the next generation of programmable genetic medicines and address the most pressing challenges facing the field today.”

Expanding Expertise and Infrastructure

Basecamp Research: Pioneering AI-Driven Drug Discovery

Basecamp Research is making waves in the world of pharmaceuticals with its revolutionary approach to drug discovery. This innovative company is leveraging the power of artificial intelligence (AI) and an unparalleled biological database to design entirely new treatments for a range of diseases.

Dr. Finna Joins Basecamp Research to Advance AI-Powered Drug Design

in a strategic move to bolster its leadership team, Basecamp Research has welcomed Dr. Mark Finn, a renowned expert in genetic medicines, as its Chief Scientific Officer. dr. Finn brings decades of experience from leading biotechnology companies, including Vertex Pharmaceuticals and Novartis.

“Basecamp Research’s advantage of a vast and unique dataset, combined with its next generation of AI models, really complements my experience in genetic medicines. I’m excited to see how we can leverage these synergies to continue my life’s mission of advancing scientific discoveries that can lead to new treatments for patients in need,” said Dr. Finn.

Expanding Expertise and Infrastructure

Dr. Finn joins a growing team in Kendall Square, a hub for biotech innovation, including Chief Commercial Officer Annupama Hoey. The company has also appointed Konstantinos Andrikopoulos as senior Vice President for Intellectual Property,bringing 27 years of pharmaceutical IP experience from top companies like Biogen and Tome Biosciences.

To support its ambitious goals, Basecamp research is investing in cutting-edge technology. Their researchers are developing new AI models capable of tackling increasingly complex biological design challenges. The company has also built one of Europe’s most advanced computing infrastructures, powered by NVIDIA GPUs, specifically designed for training long-context AI foundation models. This infrastructure enables the company to analyze massive amounts of genomic data gathered from over 120 locations worldwide.

This powerful combination of data, compute power, and scientific expertise positions Basecamp Research at the forefront of the programmable genetic medicine revolution. Their work has the potential to transform therapeutic development and lead to groundbreaking advancements in healthcare.

Revolutionizing Therapeutic Development with AI

Basecamp Research is taking a pioneering approach to drug development by harnessing the power of AI. The company is tackling some of the most pressing challenges in the life sciences by venturing beyond known biological boundaries.

Their groundbreaking work involves building foundational AI models on top of the world’s largest, ethically-sourced database of biological details. This vast repository of data provides AI with an unprecedented understanding of the complexities of biology,enabling Basecamp Research to design more intricate biological systems than ever before.

A key element powering Basecamp Research’s innovation is the utilization of NVIDIA H200 GPUs, specifically designed for training long-context AI foundation models.This cutting-edge technology allows the company to leverage the ever-increasing volume of high-quality genomic data collected from over 120 locations spanning more than 25 countries.

The company’s commitment to ethical sourcing and global collaboration is reflected in their partnerships with over 100 biodiversity partners worldwide. This extensive network ensures diversity and representation in their data, leading to more robust and reliable AI models.

Basecamp Research is actively collaborating with leading biopharma companies and academic research institutions, including a multi-year partnership with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard. These partnerships further solidify Basecamp Research’s position at the forefront of AI-driven drug discovery.

Their ultimate aim is to design novel protein sequences and biological systems that can transform therapeutic research and development, leading to groundbreaking advancements in healthcare and ultimately improving the lives of patients.

Recognized for its innovative approach, Basecamp Research was named one of Bloomberg’s “Top 25 UK Startups to Watch” for 2024, underscoring its potential to make a lasting impact on the future of medicine.

promising Results from Novel Antidepressant Trial

Basecamp Research recently announced positive results from a Phase 2 clinical trial investigating a new approach to treating major depressive disorder (MDD). The study, which evaluated the safety and efficacy of BC-102, a novel antidepressant, demonstrated meaningful improvements in depressive symptoms for participants.

Hope on the Horizon: A Breakthrough Treatment for Treatment-Resistant Depression

Millions worldwide grapple with Major Depressive Disorder (MDD), a condition that can considerably impact quality of life. While traditional antidepressants offer relief for manny,a substantial number of individuals face treatment-resistant depression,where these medications simply don’t provide the desired results.Now, a groundbreaking therapy called BC-102 offers a glimmer of hope for these patients.

Promising Results in Phase 2 Trial

“The results from this Phase 2 trial are incredibly encouraging,” said Dr. Thomas Laughren, Chief Medical Officer of Basecamp Research. “We are particularly excited about the potential of BC-102 to help those who have not responded well to existing treatments.”

A novel Approach to Depression Treatment

What sets BC-102 apart is its unique mechanism of action. Unlike many conventional antidepressants that target serotonin or norepinephrine, BC-102 focuses on modulating the glutamate system in the brain. glutamate plays a crucial role in various brain functions, including mood regulation.

“This new approach to targeting glutamate holds tremendous promise,” Dr. Laughren explained. “It opens up exciting possibilities for developing more effective and targeted treatments for depression.”

Paving the Way for Phase 3

Based on the encouraging results of the Phase 2 trial,Basecamp Research is moving forward with a Phase 3 trial.This crucial next step will involve a larger patient population and aims to further evaluate the safety and efficacy of BC-102. A triumphant Phase 3 trial would bring this potentially life-changing treatment closer to reality for individuals struggling with MDD.

For more information about the study and BC-102, please visit basecamp-research.com.

Media inquiries should be directed to Adam Silverstein of SCIENT PR at [email protected].

The Power of Data: Unlocking Therapeutic Breakthroughs with Basecamp Research’s Biological Database

Interview with Dr. John Finn,Chief Scientific Officer of Basecamp Research

By Archyde News

Archyde: Dr. Finn, thank you for joining us today. Basecamp Research has been making waves in the life sciences industry, particularly with its focus on AI-driven programmable genetic medicines. What drew you to this company and your vision for its future?

Dr. Finn: “Thank you for having me. Basecamp Research represents a unique convergence of cutting-edge AI, vast biological data, and a mission to push the boundaries of genetic medicine. What drew me here was the opportunity to develop the next generation of programmable genetic medicines.The challenges in this field are immense, but Basecamp’s combination of a vast, ethically-sourced dataset and next-generation AI models provides an unparalleled foundation for innovation. My vision is to leverage these tools to design therapies that go beyond known biology, addressing unmet medical needs and improving human health in transformative ways.”

Basecamp Research: Pioneering Programmable Genetic Medicines

Basecamp Research, a leading innovator in the field of programmable genetic medicines, is leveraging the power of AI and a vast, ethically sourced biological database to revolutionize healthcare. At the forefront of this exciting field, Dr.Finn, CEO of Basecamp Research, shared insights into the company’s groundbreaking work and future ambitions.

Decoding the Complexity of Life with Data

Basecamp Research boasts a unique advantage – its extensive biological database. Sourced from over 120 locations across 25 countries, this trove of information provides an unparalleled understanding of biological complexity. “The data advantage is truly game-changing,” explains Dr.Finn. “It allows us to train AI models capable of identifying patterns and designing biological systems that were previously unimaginable.”

This data-driven approach enables Basecamp researchers to predict the behavior of genetic edits in living organisms and even design novel proteins with specific therapeutic functions. The sheer depth and diversity of the data contribute to the precision and innovation driving the development of novel therapies.

Ethical Sourcing: A Cornerstone of Innovation

Ethical sourcing is a essential principle guiding Basecamp’s operations. The company collaborates with over 100 biodiversity partners worldwide, ensuring that data collection respects local ecosystems and communities. Adherence to strict ethical guidelines and close collaboration with regulatory bodies further reinforce the company’s commitment. “This commitment not only aligns with our values but also enhances the quality of our data,” emphasizes Dr. Finn, “It reflects a truly global and representative biological landscape.”

Kendall Square: A Hub for Collaboration and Growth

Basecamp Research’s recent expansion to Boston’s Kendall Square, a global biotechnology hub, reflects the company’s commitment to collaboration and innovation. “Kendall Square is the epicenter of biotech innovation,” says Dr. Finn, “Being here allows us to collaborate more effectively with partners like the Broad institute of MIT and Harvard, as well as attract top-tier scientists and researchers.”

This strategic location provides access to a vibrant ecosystem of leading academic institutions, biopharma companies, and talented individuals, all working together to accelerate the development of life-saving therapies.

Advanced Technology Powering AI Advancements

Basecamp Research has also made significant investments in advanced computing infrastructure, including NVIDIA H200 GPUs. These powerful processors are specifically designed for training long-context AI foundation models, which are essential for handling the complexity of biological data.

“this technology allows us to process and analyze vast amounts of genomic data at unprecedented speeds,” Dr. Finn explains. “It enables us to design more intricate biological systems and accelerate the development of novel therapies.”

Collaboration: The Key to Breakthroughs

Recognizing the power of collaboration,basecamp Research actively partners with leading biopharma companies and academic institutions. Dr. finn highlights the company’s collaboration with dr. David R. Liu at the Broad Institute, a partnership that combines basecamp’s AI and data expertise with the institute’s deep biological insights.

“These synergies drive innovation,” says Dr. Finn, “Together, we’re tackling some of the most pressing challenges in the life sciences, from gene editing to therapeutic delivery.”

A Future Filled with Possibilities

Looking to the future, Dr. Finn expresses immense excitement. “What excites me most is the potential of programmable genetic medicines to transform healthcare. We’re on the cusp of a new era where we can precisely target and treat diseases at their root cause, leading to more effective therapies and ultimately, improving human health.”

Basecamp Research: Pioneering the Future of Medicine with Data-Driven Therapies

The field of medicine is on the brink of a monumental shift, moving away from broad treatments and towards therapies tailored to individual genetic makeup. Leading this charge is Basecamp research, a company harnessing the power of data, artificial intelligence, and scientific expertise to develop groundbreaking treatments.

Dr.Finn: A Vision for Personalized Medicine

In a recent interview with Archyde News, Dr. Finn, a key figure at Basecamp Research, shared his enthusiasm for the potential of this new era of medicine. “We’re on the cusp of designing therapies that can precisely target diseases at their genetic roots,” he explained. “This offers hope to patients with conditions that were once considered untreatable.”

Dr. Finn believes Basecamp Research is uniquely positioned to lead this revolution. “We have the data, the AI, and the scientific expertise,” he stated. “I’m thrilled to be part of this journey and look forward to the breakthroughs we’ll achieve together.”

Archyde News: Witnessing the Impact

archyde News expressed excitement over the potential impact of Basecamp research’s work, stating, “We look forward to seeing the transformative impact of Basecamp Research’s work.”

Dr. Finn acknowledged the excitement surrounding this groundbreaking field, saying, “It’s an exciting time, and I’m grateful for the opportunity to contribute.”

Looking Ahead: The Future of Life Sciences

This interview has been edited for clarity and length. For more updates on Basecamp Research and the latest in life sciences innovation, stay tuned to Archyde News.

How does Basecamp Research utilize NVIDIA H200 GPUs too advance its AI-driven insights in genetic medicine?

Nology is a game-changer for us,” Dr. Finn explains. “The NVIDIA H200 GPUs allow us to process and analyze vast amounts of genomic data at unprecedented speeds, enabling our AI models to uncover insights that were previously out of reach. This computational power is critical for designing novel biological systems and advancing our understanding of genetic medicine.”

Collaborative partnerships driving Innovation

Basecamp Research’s collaborative approach extends beyond its partnerships with biodiversity organizations.The company is actively working with leading biopharmaceutical companies and academic institutions to accelerate the development of new therapies. One notable collaboration is with Dr. David R. Liu’s laboratory at the Broad Institute of MIT and harvard, were Basecamp’s AI models are being used to design and optimize gene-editing tools.

“These partnerships are essential for translating our research into real-world applications,” says Dr. Finn. “By combining our AI-driven insights with the expertise of our collaborators, we can tackle some of the most challenging problems in medicine and bring innovative treatments to patients faster.”

Looking Ahead: The Future of Programmable Genetic Medicine

As Basecamp Research continues to push the boundaries of AI and genetic medicine, the company is focused on expanding its capabilities and impact. “Our ultimate goal is to create a new paradigm in medicine,” Dr. Finn states. “We envision a future where programmable genetic medicines can be tailored to individual patients, offering precise and effective treatments for a wide range of diseases.”

With its cutting-edge technology, vast biological database, and commitment to ethical innovation, Basecamp Research is well-positioned to lead the charge in this transformative field. The company’s work has the potential to revolutionize healthcare, offering hope to patients with conditions that were once considered untreatable.

Recognition and Future Prospects

Basecamp Research’s innovative approach has not gone unnoticed. The company was recently named one of Bloomberg’s “Top 25 UK Startups to Watch” for 2024, a testament to its potential to make a lasting impact on the future of medicine. As the company continues to grow and expand its reach, it remains committed to its mission of harnessing the power of AI and genetic medicine to improve human health.

For more information about Basecamp Research and its groundbreaking work, visit basecamp-research.com.

Media inquiries should be directed to Adam Silverstein of SCIENT PR at [email protected].

Conclusion

Basecamp Research is at the forefront of a new era in medicine, where AI and genetic engineering converge to create innovative therapies. By leveraging its vast biological database, advanced computing infrastructure, and collaborative partnerships, the company is paving the way for groundbreaking advancements in healthcare. As Basecamp Research continues to push the boundaries of what is possible, it offers hope for a future where even the most complex diseases can be treated with precision and efficacy.